Complete Response of Relapsed Systemic and Cutaneous Anaplastic Large Cell Lymphoma Using Brentuximab Vedotin: 2 Case Reports

被引：12
|
作者：
Broccoli, Alessandro [1 ]
Derenzini, Enrico [1 ]
Pellegrini, Cinzia [1 ]
Narducci, Riccardo [1 ]
Stefani, Giulia [1 ]
Casadei, Beatrice [1 ]
Argnani, Lisa [1 ]
Zinzani, Pier Luigi [1 ]
机构：
[1] Univ Bologna, Inst Hematol & Med Oncol L eA Seragnoli, Bologna, Italy
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2013年 / 13卷 / 04期
关键词：
Anaplastic large cell lymphoma; Anaplastic lymphoma kinase negative; Brentuximab vedotin; Cutaneous T-cell lymphoma; lmmunotherapy; PERIPHERAL T-CELL; SGN-35;
D O I：
10.1016/j.clml.2013.03.008
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：493 / 495
页数：3
相关论文
共 50 条
  • [1] Cutaneous Anaplastic Large-Cell Lymphoma with Dramatic Response to Brentuximab Vedotin
    Sahin, Mustafa
    Miskioglu, Mine
    Inanir, Isil
    Akar, Hikmet
    Nese, Nalan
    Temiz, Peyker
    Aydogdu, Ismet
    TURKISH JOURNAL OF HEMATOLOGY, 2021, 38 (01) : 85 - 87
  • [2] The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
    Senter, Peter D.
    Sievers, Eric L.
    NATURE BIOTECHNOLOGY, 2012, 30 (07) : 631 - 637
  • [3] The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
    Peter D Senter
    Eric L Sievers
    Nature Biotechnology, 2012, 30 : 631 - 637
  • [4] Complete Remissions with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
    Shustov, Andrei R.
    Advani, Ranjana
    Brice, Pauline
    Bartlett, Nancy L.
    Rosenblatt, Joseph D.
    Illidge, Tim
    Matous, Jeffrey
    Ramachandren, Radhakrishnan
    Fanale, Michelle A.
    Connors, Joseph M.
    Yang, Yin
    Sievers, Eric L.
    Kennedy, Dana A.
    Pro, Barbara
    BLOOD, 2010, 116 (21) : 423 - 424
  • [5] Brentuximab vedotin: treatment role for relapsed refractory systemic anaplastic large-cell lymphoma
    Lai, Chao-Ming
    Horowitz, Sandra
    EXPERT REVIEW OF HEMATOLOGY, 2013, 6 (04) : 361 - 373
  • [6] Relapsed or refractory anaplastic large cell lymphoma: Brentuximab vedotin of course!
    Paillassa, Jerome
    HEMATOLOGIE, 2018, 24 (01): : 19 - 21
  • [7] Cost-effectiveness of brentuximab vedotin in relapsed or refractory systemic anaplastic large cell lymphoma
    Hux, Margaret
    Zou, Denise
    Ma, Esprit
    Sajosi, Peter
    Engstrom, Andreas
    Selby, Ross
    Benson, Eugene
    Teasell, Jeremy
    Richhariya, Akshara
    Briggs, Andrew
    Bonthapally, Vijayveer
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (07)
  • [8] Improvement of Cutaneous Anaplastic Large Cell Lymphoma by Brentuximab Vedotin Monotherapy
    Onaka, Takashi
    Kitagawa, Tomoya
    Kawakami, Chika
    Yonezawa, Akihito
    TURKISH JOURNAL OF HEMATOLOGY, 2018, 35 (02) : 135 - 136
  • [9] Brentuximab vedotin in anaplastic large cell lymphoma
    Skarbnik, Alan P. Z.
    Smith, Mitchell R.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2012, 12 (05) : 633 - 639
  • [10] Brentuximab vedotin for previously untreated systemic anaplastic large cell lymphoma
    Calleja, Anne
    Bouclet, Florian
    BULLETIN DU CANCER, 2021, 108 (01) : 12 - 13
12345